Clicky

Bristol Myer Squi Pf(BMYMP) News

Date Title
Apr 26 Bristol-Myers Squibb First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Apr 24 Bristol Myers Squibb Reverses Its Losing Spree On First-Quarter Beat
Apr 24 Bristol-Myers Squibb (NYSE:BMY) Raises 2025 Revenue Guidance Following Strong Q1 Performance
Apr 24 Netflix's new high, Bristol Myers outlook, Texas Instruments pops
Apr 24 Bristol Myers Squibb Reports First Quarter Financial Results for 2025
Apr 22 Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia
Apr 22 Bristol Myers Dives After Promising Schizophrenia Drug Flops In Phase 3 Test
Apr 22 Patent Cliff Looms Large for Bristol-Myers Squibb Stock (BMY)
Feb 16 New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis
Feb 13 Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial
Feb 12 Shareholders in Bristol-Myers Squibb (NYSE:BMY) have lost 7.2%, as stock drops 5.4% this past week
Feb 11 The Magnificent 7 Are So Last Year. Cash Cows Are the New Kings.
Feb 10 Bristol Myers Squibb Announces Positive Topline Results for Breyanzi® (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma
Jan 3 Bristol Myers Squibb to Present at J.P. Morgan’s 43rd Annual Healthcare Conference
Jan 2 Bristol-Myers Squibb's (NYSE:BMY) investors will be pleased with their 2.4% return over the last five years
Oct 3 U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)
Oct 3 Bristol-Myers Squibb's Profits, Stock Price Kick Into High Gear
Oct 1 Read This Before Considering Bristol-Myers Squibb Company (NYSE:BMY) For Its Upcoming US$0.60 Dividend
Sep 30 Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies
Sep 27 U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults